Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Hematologic Oncology Update
00:00
Would lisocabtagene be preferred in mantle cell?
Dr Lunning notes he would likely choose lisocabtagene if available for mantle cell, but approvals affect real‑world choices.
Play episode from 48:47
Transcript
